Ardour Capital Downgrades Metabolix (MBLX) to Reduce
More News related to MBLX
- Metabolix (MBLX) Prices 3.45M Shares at $9/Share
- Metabolix Announces Completion of Common Stock Offering
- Morning Movers 11/11: NCST, SMI, MSN, CHLN, NLST, REGN Higher; TGIC, STS, CLWR, STV, MHR, MBLX Lower
- Metabolix (MBLX) Announces 3M Common Share Offering at $9/Share
- Metabolix Prices Common Stock Offering
More News related to Downgrades
- Hoku Scientific (HOKU) Amends Poly Deal with Jinko Solar
- American International Group (AIG), Greenberg and Smith Settle Disputes
- Heska (HSKA) Announces Agreements with Roche for Blood Gas Product Supply/Affiliated Consumables
- AIG, Greenberg and Smith to settle all disputes
- DryShips (DRYS) Announces Exercise of Over-Allotment Option by Underwriters, Closes Convertible Senior Notes Offering for Net Proceeds of $448M
Ardour Capital downgrades Metabolix (Nasdaq: MBLX) to Reduce. Price target $8.
To see more analyst ratings on MBLX Click Here.
Metabolix, Inc., a bioscience company, develops and commercializes alternatives to petrochemical-based plastics, chemicals, and energy.
Related Categories
DowngradesStocks Mentioned
+0.15Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
